News & insights
Novo Nordisk
Articles from Apotek Analytics.
-

FDA tentatively approves first generic lenacapavir. Zolgensma tumour cases shake gene therapy
HIV prevention moved closer to reach in poorer countries as the FDA gave tentative approval to the first generic lenacapavir.
-

Lilly’s retatrutide beats Ozempic. Artiva drops its autoimmune cell therapy after two trial deaths
Eli Lilly’s ‘triple-G’ drug retatrutide beat Novo Nordisk’s Ozempic on blood sugar and weight loss in a head-to-head phase 3 trial in type 2 diabetes, though with more side effects and treatment discontinuations.
-

FDA approves GSK and Ionis hepatitis B drug that offers some patients a functional cure
The FDA approved bepirovirsen, a first of its kind antisense injection for chronic hepatitis B from GSK and Ionis, as dealmaking led the rest of the week’s coverage.
-

FDA approves AbbVie’s first-in-class Parkinson’s pill as pharma deal-making accelerates
The FDA approved AbbVie’s tavapadon, branded Juvmo, for adults with Parkinson’s disease, as deal-making dominated the rest of the week.